Back to Search
Start Over
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses*.
- Source :
-
Journal of Dermatological Treatment . Apr2015, Vol. 26 Issue 2, p121-123. 3p. - Publication Year :
- 2015
-
Abstract
- The Itch Severity Score (ISS), a 0-10 numeric rating scale, was used to assess pruritus due to psoriasis in a Phase 2 b trial of tofacitinib, a novel oral Janus kinase inhibitor. 197 patients with moderate-to-severe plaque psoriasis were randomized to tofacitinib 2, 5 or 15 mg twice daily, or placebo. The ISS was recorded daily from baseline to week 2 and at study visits. Following good and recommended research practice, we performed analyses to examine the clinically important differences (CID) (between-group difference or within-group difference) and clinically important responders (CIR) (within-patient change) for the ISS. The CID and CIR were defined using Patient Global Assessment of psoriasis as an anchor and were estimated with a longitudinal model. A CID on the ISS was 1.64 and, by day 10, the mean changes from baseline in ISS values for the tofacitinib doses (placebo-adjusted) exceeded CID. A CIR on the ISS was a 30% improvement from baseline and, at week 12, 87.2% to 100% of patients receiving tofacitinib reached ≥30% improvement versus 29.4% of patients receiving placebo ( p < 0.0001). Overall, the CID and CIR analyses play vital roles in the interpretation of the treatment effects measured by ISS. [ABSTRACT FROM AUTHOR]
- Subjects :
- *PSORIASIS
*ITCHING
*JANUS kinases
*PROTEIN-tyrosine kinases
*SKIN disease treatment
Subjects
Details
- Language :
- English
- ISSN :
- 09546634
- Volume :
- 26
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Journal of Dermatological Treatment
- Publication Type :
- Academic Journal
- Accession number :
- 103062639
- Full Text :
- https://doi.org/10.3109/09546634.2014.906033